Skip to main content

A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)

General Information

Age Group

Adult

Status

Recruiting

Protocol Number

NCT03834493

Background Information

The purpose of this study is to test the safety and efficacy of Pembrolizumab, also known as KEYTRUDA®, or a placebo in combination with a hormone drug (Enzalutamide) for prostate cancer

For more information go to https://clinicaltrials.gov/ct2/show/NCT03834493

Offered At

Inova Schar Cancer Institute
A department of Inova Fairfax Hospital
8081 Innovation Park Drive
Fairfax, VA 22031

Eligibility Information

  • Adult males with adenocarcinoma of the prostate without small cell histology
  • Evidence of metastatic disease
  • Additional eligibility in protocol

Ineligibility Information

  • Active autoimmune disease
  • Gastrointestinal disorders affecting absorption
  • Active central nervous system metastases
  • Additional ineligibility in protocol